Purpose
High dose rate brachytherapy (HDR-BT) is a viable treatment choice for low to high risk prostate cancer, either as monotherapy or boost following external beam. Traditionally, this has been reserved for patients with gland size less than or equal to 60cc, as recommended in the GEC-ESTRO guidelines. This study seeks to determine whether these recommendations hold true by determining if there are significant differences in clinical and dosimetric outcomes after treatment of patients with gland volumes larger and smaller than 60cc.
Methods and Materials
From November 2003 to July 2009, 197 patients with locally advanced prostate adenocarcinoma were sequentially enrolled in this study, with 164 patients forming this analysis. All were treated with HDR-BT alone using Ir-192. The median clinical target volume for our cohort was 60cc and served as an appropriate cut off for comparison. The median follow up time was 71.3 months. Biochemical relapse rate was assessed as defined by the Phoenix definition of prostate specific antigen nadir plus 2µg/l. Incidence of late genitourinary effects was determined by International Prostate Symptom Score. Dosimetric parameters V100 and D90 were used to assess the quality of implantation. Usage of androgen deprivation therapy was lower in the large gland group (71.95% compared to 89.02%, p = 0.0).
Results
This study found larger prostate volume was associated with superior biochemical control with 91% of patients free of relapse vs 78% (log-rank p = 0.01) at 6 years. This was a positive predictor for biochemical relapse in univariate and multivariate analysis. This improvement did not come at the expense of moderate (p = 0.63) or severe (p = 0.32) late genitourinary toxicity. Glands #60cc were dosimetrically non inferior in terms of D90 (p = 0.14) and V100 (p = 0.24).
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Conclusion
It is concluded that HDR-BT should not be excluded as an option for patients with prostate glands #60cc. Indeed, biochemical control has been shown to be superior in this group of patients and not at the expense of late genitourinary toxicity. This improvement cannot be explained on the basis of D90 and V100 but we believe it is reasonable to assume that coverage of the gland periphery is more readily achievable given the practicalities of planning to a larger target in which the urethra does not involve a large percentage of the treated volume. This data may also support previously published evidence that smaller glands may have worse biology tumours. Through this work we propose that cytoreduction with hormonal therapy is not necessary prior to HDR-BT for the treatment of patients with large prostate glands, particularly given the potential added toxicity and detriment to oxygenation of tissues. study using susceptibility and relaxivity dynamic MRI. Int J Radiat Oncol Biol Phys. 2011;80(3):721-7.
